Literature DB >> 26541345

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

James N Lowder1, Pietro Taverna1, Jean-Pierre J Issa2.   

Abstract

Keywords:  azacitidine; decitabine; guadecitabine; hypomethylating agents

Mesh:

Substances:

Year:  2015        PMID: 26541345     DOI: 10.2217/epi.15.66

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


× No keyword cloud information.
  3 in total

Review 1.  Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.

Authors:  Olatoyosi Odenike
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.

Authors:  Marie Anne Hospital; Norbert Vey
Journal:  Curr Oncol Rep       Date:  2020-01-23       Impact factor: 5.075

3.  Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Authors:  Gail J Roboz; Hagop M Kantarjian; Karen W L Yee; Patricia L Kropf; Casey L O'Connell; Elizabeth A Griffiths; Wendy Stock; Naval G Daver; Elias Jabbour; Ellen K Ritchie; Katherine J Walsh; David Rizzieri; Scott D Lunin; Tania Curio; Woonbok Chung; Yong Hao; James N Lowder; Mohammad Azab; Jean-Pierre J Issa
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.